Orchid Pharma has settled a case related to alleged violation of disclosure norms with markets regulator Sebi after payment of Rs 5.25 lakh as settlement charges.
In an order dated July 24, the Securities and Exchange Board of India (Sebi) settled the "possible proceedings" against Orchid Pharma related to alleged non-compliances by the firm of Sebi's ICDR (Issue of Capital and Disclosure Requirements) Regulations.
Orchid Pharma had filed an application with the regulator under settlement mechanism, that provides for settlement of cases without admitting or denying the charges.
The settlement terms proposed by the firm were considered by Sebi's High Powered Advisory Committee (HPAC), which recommended the case for settlement on payment of Rs 5.25 lakh by the company. The recommendation of HPAC was also accepted by the panel of whole-time members of the regulator.
Last month, the company paid the settlement amount of Rs 5.25 lakh and accordingly Sebi disposed of the possible proceedings.
However, Sebi said if any representation made by the firm in the settlement proceedings is subsequently discovered to be untrue, enforcement actions including commencing of proceedings can be initiated against it.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)